release review of this GPU. The reviewer, Ryan Smith, called the R9 R295X2 "beastly good" and a winner-by-default. Smith said the AMD GPU will do well because the $3,000 price tag of the Nvidia GTX Titan Z will be in a Complete Story »
GTx ( GTXI ) says CEO, Vice Chairman and co-founder ..... Hanover has served as president and COO since GTx 's inception in September 1997. SA contributor Cora Schlesinger has been bullish on GTx since April 2013, when it traded at almost
solution (relies on Nvidia's Kepler architecture) that will retail for a whopping $3K. Nvidia's current flagship (the GTX Titan Black) only goes for $999, and AMD 's top-of-the-line R9 290X ( previous ) has a $549 MSRP. Nvidia has been
s new Maxwell architecture on the low-end, and its older Kepler architecture on the high-end. The top-of-the-line GTX 880M (competes against AMD 's R9 M290X ) features 1536 cores, a 954MHz. GPU clock, and a 256-bit GDDR5 graphics RAM interface
We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.
GTx adds a European partner.
(Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...
We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.
GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to
generate substantial revenue . Acapodene is GTx 's first in - house drug candidate . The ..... traction with urologists or oncologists . GTx may not have success in repartnering Ostarine ..... large potential patient population . If GTx can establish another partnership or independently